Hypertrophic cardiomyopathy: From gene defect to clinical disease

Cell Research

Volumn 13, Issue 1, 2003, Pages 9-20

  Chung, Man Wei ^a   Tsoutsman, Tatiana ^a   Semsarian, Christopher ^a,b  

^a CENTENARY INSTITUTE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cardiomyopathy; Gene; Hypertrophy; Modifying factors; Mutations; Signalling

Indexed keywords

ANIMALIA;

ANIMAL; CARDIOMYOPATHY; GENETICS; GENOTYPE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; MOUSE; MUTATION; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; RABBIT; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SARCOMERE;

ANIMALS; CARDIOMYOPATHIES; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOMYOPATHY, RESTRICTIVE; GENOTYPE; HUMANS; MALE; MICE; MUTATION; PHENOTYPE; RABBITS; SARCOMERES;

EID: 0642280767     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/sj.cr.7290146     Document Type: Review

References (72)

1. Watson J, Crick F. Molecular structure of nucleic acids. Nature 1953; 171:737-8.
2. Pennisi E. Finally, the Book of Life and instructions for navigating it. Science 2000; 288:2304-7.
3. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958; 20:1-8.
4. Seidman CE, Seidman JG. Molecular genetic studies of familial hypertrophic cardiomyopathy. Basic Res Cardiol 1998; 93:13-6.
5. Maron BJ, Gardin JM, Flack JM, Gidding SS, Bild D. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 1995; 92:785-9.
6. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775-85.
7. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986; 7:204-14.
8. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes-clinical, demographic and pathological profiles. JAMA 1996; 276:199-204.
9. Semsarian C, Richmond DR. Sudden cardiac death in familial hypertrophic cardiomyopathy: an Australian experience. Aust NZ J Med 1999; 29:368-70.
10. Semsarian C, Maron BJ. Sudden cardiac death in the young. Med. J. Aust 2002; 176:148-9.
11. Maron BJ, Spirito P, Wesley Y, et al. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 1986; 315:610.
12. Semsarian C, Jeremy RW, French J, Trent R, Richmond DR. Natural history of wall thickening in hypertrophic cardiomyopathy. Aust NZ J Med 1997; 27:51-8.
13. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy -related death: revisited in a large non-referral-based patient population. Circulation 2000; 102:858-64.
14. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287:1308-20.
15. Jarcho JA, McKenna WJ, Pare JAP, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 1989; 321:1372.
16. Anan R, Greve G, Thierfelder L, et al. Prognostic implications of novel b-cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994; 93:280-5.
17. Watkins H, Rosenzweig A, Hwang D, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992; 326:1108-14.
18. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardiomyopathy. Circulation 1994; 89:22-9.
19. Watkins H, Conner D, Thierfelder L, et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995; 11 :434-7.
20. Nimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998; 338:1248-57.
21. Gilbert R, Kelly MG, Mikawa T, et al. The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle. J Cell Science 1996; 109:101-11.
22. Gautel M, Zuffardi O, Freiburg A, et al. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? EMBO J 1995; 14:1952-60.
23. Yu B, French J, Carrier L, Jeremy RW, et al. Molecular pathology of familial hypertrophic cardiomyopathy caused by mutations in the cardiac myosin binding protein C gene. J Med Genet 1998; 35:205-10.
24. Watkins H, McKenna WJ, Thierfelder L, et al. The role of cardiac troponin T and ??tropomyosin mutations in hypertrophic cardiomyopathy. N Engl J Med 1995; 332:1058.
25. Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation. 2001; 104:1380-4.
26. Anan R, Shono H, Kisanuki A, Arima S, Nakao S, Tanaka H. Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favourable prognosis. Circulation 1998; 98:391-7.
27. Coviello DA, Maron BJ, Spirito P, et al. Clinical features of hypertrophic cardiomyopathy caused by mutation of a ot spot? in the tropomyosin gene. J Am Coll Cardiol 1996; 29:635-40.
28. Poetter K, Jiang H, Hassanzadeh S, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 1996; 13:63-9.
29. Lee W-H, Hwang TH, Kimura A, et al. Different expressivity of a ventricular essential myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy. Am Heart J 2001; 141:184-9.
30. Kimura A, Harada H, Park J-E et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997; 16:379-82.
31. Kokado H, Shimizu, M, Hirouki Y, et al. Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. Circulation 2000; 102:663-9.
32. Woo A, Rakowski H, Liew J, et al. Hypertrophic cardiomyopathy: genotypic and phenotypic heterogeneity. Circulation 2000; 102:169-78.
33. Pascale R, Charron P, Carrier L, et al. Distribution of disease gene in 102 genotyped families with hypertrophic cardiomyopathy. Circulation 2001; 104: II521.
34. Yamaguchi H, Ishimura T, Nishiyama S, et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (Apical hypertrophy): ventriculographic echocardiographic features in 30 patients. Am J Cardiol 1979; 44:401-12.
35. Mogensen J, Klausen IC, Pedersen AK, et al. a-cardiac actin is a novel gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999; 103:39R-43R.
36. Oson TM, Doan TP, Kishimoto NY, et al. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000; 32:1687-94.
37. Satoh M, Takahashi M, Sakamoto T, Hiroe M, Marumo F, Kimura A: Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem Biophys Res Commun 1999; 262:411-7.
38. Niimura H, Patton K, McKenna, W, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 2002; 105:446-51.
39. Gollob MH, Green MS, Tang AS et al. Identification of a gene responsible for Wolff- Parkinson-White syndrome. N Engl J Med 2001; 344:1823-31.
40. Blair E, Redwood C, Ashrafian H, et al. Mutations in the gamma(2) subunit of AMP- activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Molec Genet 2001; 10:1215-20.
41. Arad M, Benson W, Perez-Atayde AR et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002; 109:357-62.
42. Lankdord EB, Epstein ND, Fananapazir L, et al. Abnormal contractile properties of muscle fibers expression b-myosin chain mutations in patients with hypertrophic cardiomyopathy. J Clin Invest 1995; 95:1409-14.
43. Fananapazir L, Dalakis MC, Cyran F, et al. Missense mutations in the b- myosin heavy chain cause central core disease in hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 1993; 90:3993-7.
44. Rayment I, Holden HM, Sellers JR, et al. Structural interpretation of the mutations in the b-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 1995; 92:3868-94.
45. Sweeney HL, Straceski AJ, Leinwand LA, et al. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J Biol Chem 1994; 269:1603-5.
46. Sata M, Ikebe M: Functional analysis of the mutations in the human cardiac ?- myosin that are responsible for familial hypertrophic cardiomyopathy. J Clin Invest 1996; 98:2866-73.
47. Lin D, Bobkova A, Homsher E, et al. Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. J Clin Invest 1996; 97:2842-8.
48. Watkins H, Seidman CE, Seidman JG, et al. Expression and functional assessment of a truncated cardiac troponin T that cause hypertrophic cardiomyopathy: evidence for a dominant negative action. J Clin Invest 1996; 11:2456-61.
49. Marian AJ, Zhao G, Seta Y, Roberts R, Yu QT. Expression of mutant (Arg92Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocyte contractility. Circ Res 1997; 81:76-85.
50. Rust EM, Albayya FP, Metzger JM. Identification of a contractile deficit in adult cardiac myocytes expressing hypertrophic cardiomyopathy-associated mutant troponin T proteins. J Clin Invest 1999; 103:1459-67.
51. Watkins H, Seidman CE, Seidman JG, Feng HS, Sweeney HL. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy: evidence for a dominant negative action. J Clin Invest 1996; 98:2456-61.
52. Michele DE, Albayya FP, Metzger JM. Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant a-tropomyosins in adult cardiac myocytes. Nat Med 1999; 5:1413-7.
53. Vikstrom KL, Factor SM, Leinwand LA. A murine model of hypertrophic cardiomyopathy. Zeitschrift fur Kardiologie 1995; 84:49-54.
54. Marian AJ, Wu Y, McCluggage M, et al. A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest 1999; 104:1683-92.
55. Oberst L, Zhao G, Park JT, et al. Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Invest 1998; 102:1498-505.
56. Tardiff JC, Factor SM, Tompkins BD, et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest 1998; 101:2800-11.
57. Yang Q, Sanbe A, Osinka H, et al. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J Clin Invest 1998; 102:1292-300.
58. James J, Zhang Y, Osinska H, et al. Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. Circ Res 2000; 87:805-11.
59. Geisterfer-Lowrance AAT, Christe M, Conner DA, et al. A murine model of familial hypertrophic cardiomyopathy. Science 1996; 272:731-4.
60. McConnell BK, Fatkin D, Semsarian C, et al. Comparison of two murine models of familial hypertrophic cardiomyopathy. Circ Res 2001; 88:383-9.
61. Tyska MJ, Hayes E, Giewat M, et al. Single molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res 2000; 86:737-44.
62. Semsarian C, Ahmad I, Giewat M, et al. The L-type calcium-channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 2002; 109:1013-20.
63. Fatkin D, McConnell BK, Mudd JO, et al. An abnormal Ca2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest 2000; 106:1351-9.
64. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001;103:789-91.
65. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104:317-24.
66. Semsarian C, Fatkin D, Healey MJ, et al. A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001; 33:2055-60.
67. Fatkin D, Christe ME, Aristizabal O, et al. Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the alpha cardiac myosin heavy chain gene. J Clin Invest.; 103:147-53.
68. McConnell BK, Jones KA, Fatkin D, et al. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J Clin Invest 1999; 104:1235-44.
69. Berul C, Christie M, Aronovitz MJ et al. Electrophysiological abnormalities and arrhythmias in ? MHC mutant familial hypertrophic cardiomyopathy mice. J Clin Invest 1997; 99:570-6.
70. Berul CI, McConnell BK, Wakimoto H, et al. Ventricular arrhythmia vulnerability in cardiomyopathic mice with homozygous mutant myosin-binding protein C gene. Circulation 2001; 104:2734-9.
71. Bruneau, BG, Nemer G, Schmitt JP, et al. Murine model of Holt-Oram syndrome defines roles of the T-box transcription facto Tbx5 in cardiogenesis and disease. Cell 2001; 106:709-22.
72. Semsarian C, Seidman CE. Molecular medicine in the 21st century. Intern Med J 2001; 31:53-9.